CPIX - Bathi resik saben saham (EPS TTM) Cumberland Pharmaceuticals Inc

The 12-month rolling specific income metric helps determine the boundaries of the business's fundamental value, while -0.79 describes the current status of the metric. Cumberland Pharmaceuticals (CPIX) faces pressure from generics and regulatory pricing risks. However, a diversified portfolio of FDA-approved products reduces revenue volatility, and exclusive contracts in intensive care units ensure the stability of Cumberland Pharmaceuticals' market positions.
CPIX (Cumberland Pharmaceuticals): rincian analitis lan laporan miturut indikator

The metric is calculated by dividing the aggregate net income over the last four quarters by the total number of shares outstanding. This metric determines the actual amount of equity income available to the owner of a single security. For Cumberland Pharmaceuticals (CPIX), a diversified portfolio of FDA-approved drugs stabilizes this financial result. The current value of -0.79 reflects the efficiency of monetizing niche products. Analyzing the rolling year earnings per share allows for an assessment of the business's resilience to market volatility.